-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech wins U.S. patent covering Ampligen-Keytruda combo cancer therapy through 2039

PUBT·08/31/2026 12:51:23
Listen to the news
AIM ImmunoTech wins U.S. patent covering Ampligen-Keytruda combo cancer therapy through 2039
  • AIM ImmunoTech won a new U.S. patent covering Ampligen (rintatolimod) used with Merck’s Keytruda (pembrolizumab) to treat cancer.
  • Patent term runs to Dec. 20, 2039, extending the company’s oncology intellectual property around Ampligen combination therapy.
  • Broadest claim covers Ampligen-Keytruda treatment across cancers when the combination outperforms either drug alone.
  • Company also cited other Ampligen checkpoint-combination patents, including a U.S. patent expiring Aug. 9, 2039.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310851PRIMZONEFULLFEED9817926) on August 31, 2026, and is solely responsible for the information contained therein.